糖心vlog

This Viewpoint proposes ways states can control the costs of expensive drugs produced by single manufacturers, including importation from other countries, international benchmark pricing, and statewide upper payment limits.

In this Viewpoint, Peter Bach and colleague Stacie Dusetzina question the assumption underlying a 2019 proposed federal rule change to eliminate drug manufacturer rebates to pharmacy benefit managers (PBMs) as a way to decrease prescription drug prices, and they propose more extensive restructuring, including a cap on out-of-pocket spending for Medicare Part D beneficiaries, to better control drug costs and save patients money.

This Viewpoint reviews proposed changes to regulations governing Canada鈥檚 Patented Medicine Process Review Board, a group mandated by Canada鈥檚 government to ensure manufacturers do not charge excessive drug prices, including use of cost-utility analyses to define excessive pricing, revision of reference country comparisons, and reducing regulatory burdens for generic drugs.

This Viewpoint discusses the costs of emerging therapies for conditions prevalent in the US Baby Boomer population now entering old age and proposes principles to ensure the value and accessibility of new expensive drugs including cost-effectiveness (CE) assessments, price-benefit alignment, and incorporation of CE data into clinical practice guidelines.